CD47 and glioblastoma: Zhang et al found that autophagy occurring in glioblastoma cells could mitigate the immunotherapeutic efficacy of anti‐CD47‐SIRPα treatment, displaying as the reduced macrophage‐derived phagocytosis and subsequent attenuation of CD8+ T‐cell cytotoxicity.23